Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment--synthesis, biological evaluation and molecular modeling studies

K. Spilovska, J. Korabecny, J. Kral, A. Horova, K. Musilek, O. Soukup, L. Drtinova, Z. Gazova, K. Siposova, K. Kuca,

. 2013 ; 18 (2) : 2397-418.

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc13031585

A structural series of 7-MEOTA-adamantylamine thioureas was designed, synthesized and evaluated as inhibitors of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE). The compounds were prepared based on the multi-target-directed ligand strategy with different linker lengths (n = 2-8) joining the well-known NMDA antagonist adamantine and the hAChE inhibitor 7-methoxytacrine (7-MEOTA). Based on in silico studies, these inhibitors proved dual binding site character capable of simultaneous interaction with the peripheral anionic site (PAS) of hAChE and the catalytic active site (CAS). Clearly, these structural derivatives exhibited very good inhibitory activity towards hBChE resulting in more selective inhibitors of this enzyme. The most potent cholinesterase inhibitor was found to be thiourea analogue 14 (with an IC₅₀ value of 0.47 µM for hAChE and an IC₅₀ value of 0.11 µM for hBChE, respectively). Molecule 14 is a suitable novel lead compound for further evaluation proving that the strategy of dual binding site inhibitors might be a promising direction for development of novel AD drugs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031585
003      
CZ-PrNML
005      
20131008104833.0
007      
ta
008      
131002s2013 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules18022397 $2 doi
035    __
$a (PubMed)23429378
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Spilovska, Katarina $u Department of Toxicology, Trebesska 1575, Faculty of Military Health Sciences, University of Defence, 50001 Hradec Kralove, Czech Republic.
245    10
$a 7-Methoxytacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer's disease treatment--synthesis, biological evaluation and molecular modeling studies / $c K. Spilovska, J. Korabecny, J. Kral, A. Horova, K. Musilek, O. Soukup, L. Drtinova, Z. Gazova, K. Siposova, K. Kuca,
520    9_
$a A structural series of 7-MEOTA-adamantylamine thioureas was designed, synthesized and evaluated as inhibitors of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE). The compounds were prepared based on the multi-target-directed ligand strategy with different linker lengths (n = 2-8) joining the well-known NMDA antagonist adamantine and the hAChE inhibitor 7-methoxytacrine (7-MEOTA). Based on in silico studies, these inhibitors proved dual binding site character capable of simultaneous interaction with the peripheral anionic site (PAS) of hAChE and the catalytic active site (CAS). Clearly, these structural derivatives exhibited very good inhibitory activity towards hBChE resulting in more selective inhibitors of this enzyme. The most potent cholinesterase inhibitor was found to be thiourea analogue 14 (with an IC₅₀ value of 0.47 µM for hAChE and an IC₅₀ value of 0.11 µM for hBChE, respectively). Molecule 14 is a suitable novel lead compound for further evaluation proving that the strategy of dual binding site inhibitors might be a promising direction for development of novel AD drugs.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $7 D000544
650    _2
$a amantadin $x chemická syntéza $x chemie $x farmakologie $x terapeutické užití $7 D000547
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $x terapeutické užití $7 D002800
650    12
$a dimerizace $7 D019281
650    _2
$a enzymatické testy $7 D057075
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    12
$a molekulární modely $7 D008958
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a referenční standardy $7 D012015
650    _2
$a takrin $x analogy a deriváty $x chemická syntéza $x chemie $x farmakologie $x terapeutické užití $7 D013619
650    _2
$a thiomočovina $x chemie $7 D013890
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Korabecny, Jan $u -
700    1_
$a Kral, Jan $u -
700    1_
$a Horova, Anna $u -
700    1_
$a Musilek, Kamil $u -
700    1_
$a Soukup, Ondrej $u -
700    1_
$a Drtinova, Lucie $u -
700    1_
$a Gazova, Zuzana $u -
700    1_
$a Siposova, Katarina $u -
700    1_
$a Kuca, Kamil $u -
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 18, č. 2 (2013), s. 2397-418
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23429378 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20131008105355 $b ABA008
999    __
$a ok $b bmc $g 995672 $s 830030
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 18 $c 2 $d 2397-418 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20131002

Find record

Citation metrics

Archiving options